SCLN 8.51 Sciclone Pharmaceuticals $SCLN Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
SCLN 8.51 Sciclone Pharmaceuticals $SCLN Hit a 52 week high of 8.53 Closing the day 09:44 at 8.51 +0.08 +0.95% With a day low of 8.22 and a total volume of 129,826.

SCLN Recent Posts: http://investorshangout.com/Sciclone-Pharmace...CLN-55380/

SCLN Sciclone Pharmaceuticals Recent Headline News

Update: SciClone Pharmaceuticals Exceeds Earnings Estimates For Q3
David Zanoni - at Seeking Alpha - Sat Nov 15, 12:21AM CST

SCLN: 8.40 (-0.03)

Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 55.2% (SCLN)
Comtex SmarTrend(R) - Fri Nov 14, 4:46PM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 3 months, Sciclone Pharmaceuticals has returned 55.25% as of today's recent price of $8.43.
SCLN: 8.40 (-0.03)

SciClone reports lower Q3 2014 GAAP net income of USD7.9m
M2 - Wed Nov 12, 7:18AM CST
Pharmaceutical company SciClone Pharmaceuticals (NasdaqGS:SCLN) disclosed on Tuesday its GAAP net income of USD7.9m (USD0.16 & USD0.15 per share, basic and diluted, respectively) for the Q3 2014.
SCLN: 8.40 (-0.03)

SciClone Pharma ups earnings guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:47AM CST

SCLN: 8.40 (-0.03)

SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:47PM CST

SCLN: 8.40 (-0.03)

SciClone Pharmaceuticals (SCLN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 3:25PM CST

SCLN: 8.40 (-0.03)

SciClone Pharmaceuticals beats by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:16PM CST

SCLN: 8.40 (-0.03)

SciClone Reports Financial Results for the Third Quarter 2014
Marketwired - Mon Nov 10, 3:06PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter 2014.
SCLN: 8.40 (-0.03)

Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST

HK: 3.03 (-0.07), WWD: 51.55 (+0.52), LLNW: 2.62 (-0.03), FXEN: 2.63 (-0.09), RMTI: 10.54 (+0.02), CZR: 15.76 (-0.74), EGY: 6.50 (-0.56), ICUI: 86.78 (+1.07), ICEL: 7.15 (-0.44), SAAS: 8.65 (-0.09), DMD: 5.50 (-0.15), NPSP: 29.59 (+0.59), SCLN: 8.40 (-0.03), ATHX: 1.38 (+0.01), CMLS: 3.58 (-0.08), TC: 2.05 (+0.02), ATW: 36.09 (+0.61), CLUB: 5.64 (-0.02), RAX: 42.77 (-0.48), PTLA: 26.47 (-0.10), IPAR: 26.94 (-0.68), ATLS: 35.98 (-0.11), AMBC: 25.89 (-0.59), CUI: 7.00 (-0.02), PDLI: 7.92 (+0.13), OMER: 19.29 (+0.31), PRAA: 59.07 (-0.92), CARA: 8.38 (-0.02), HALO: 8.60 (+0.06), MODN: 10.17 (-0.20), CALL: 8.84 (+0.22), ASEI: 46.24 (+0.12), HGR: 18.52 (-2.68), ERII: 4.65 (-0.01)

Sciclone Pharmaceuticals Has Returned 41.6% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Fri Nov 07, 10:59AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 3 months, Sciclone Pharmaceuticals has returned 41.62% as of today's recent price of $7.69.
SCLN: 8.40 (-0.03)

SciClone to Present at Jefferies Global Healthcare Conference on November 19th
Marketwired - Thu Nov 06, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Jefferies Global Healthcare Conference on November 19, 2014, at 4:20 pm GMT, taking place at the Waldorf Hilton Hotel in London, England.
SCLN: 8.40 (-0.03)

SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2014 on November 10th
Marketwired - Thu Oct 30, 5:01AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter 2014 on Monday, November 10, 2014. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
SCLN: 8.40 (-0.03)

Sciclone Pharmaceuticals Shares Up 44.4% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Fri Oct 24, 9:09AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 2 months, Sciclone Pharmaceuticals has returned 44.38% as of today's recent price of $7.84.
SCLN: 8.40 (-0.03)

3 Biotech Stocks Near 52-Week Highs Worth Selling
Motley Fool Staff - Motley Fool - Wed Oct 22, 12:01PM CDT
With markets dropping-and-popping this month investors are right to wonder whether rising volatility means that it's a good time to be moving out of high flying stocks. But just because a stock is hitting new highs doesn't mean that it isn't a great...
MACK: 8.73 (+0.25), BCRX: 10.19 (+0.12), BAX: 71.69 (-0.06), SCLN: 8.40 (-0.03), GSK: 45.83 (+0.09), CELG: 104.48 (+0.43)

Sciclone Pharmaceuticals Shares Up 26.7% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Thu Oct 09, 11:01AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 2 months, Sciclone Pharmaceuticals has returned 26.70% as of today's recent price of $6.88.
SCLN: 8.40 (-0.03)

Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 27.3% (SCLN)
Comtex SmarTrend(R) - Thu Oct 02, 9:42AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 2 months, Sciclone Pharmaceuticals has returned 27.26% as of today's recent price of $6.91.
SCLN: 8.40 (-0.03)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 3

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 1

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 6

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 2

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 7

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 2

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 0

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading

Top 5 Most Recently Viewed Articles

Teamsters at Seattle Airport Vote to Strike Against Swissport

Updated Category News Views 268

Teamsters at Seattle Airport Take Bold Action In a significant move toward ensuring safe and fair labor practices, air fuelers at Seattle-Tacoma International Airport have voted unanimously to authorize a strike against Swissport, a leading provider of ground services in the aviation industry. With over 150 workers represented by Teamsters Local 174, this decision stems...

Continue Reading
Innovative Microgrid Management System by Aspen Technology

Updated Category News Views 182

Aspen Technology Introduces Advanced Microgrid Management System Aspen Technology, Inc. (NASDAQ: AZPN), a leader in industrial software, has unveiled its innovative Microgrid Management System™ (MMS). This cutting-edge solution is designed for industries with substantial energy demands, particularly in refining, chemicals, and mining. It enables organizations to...

Continue Reading
LVGEA Reaccreditation: Economic Promises or Just Hype?

Updated Category News Views 158

So here’s the scoop: The Las Vegas Global Economic Alliance (LVGEA) just snagged its AEDO badge again from the International Economic Development Council (IEDC) on February 17, 2026. But let’s peel back that shiny veneer—what's really brewing under this celebratory announcement? Sure, they’ve been riding high since first getting accredited in January 2018, but...

Continue Reading
SL Green Realty Corp. Declares Monthly and Quarterly Dividends

Updated Category News Views 167

Overview of SL Green Realty Corp. SL Green Realty Corp., known as Manhattan's largest office landlord, plays a significant role in the commercial real estate sector. The company operates as a fully integrated real estate investment trust (REIT), concentrating on acquiring, managing, and enhancing the value of commercial properties situated throughout Manhattan. Dividend...

Continue Reading
Exciting New Homes Launch at Paloma in Summit Park

Updated Category News Views 128

Discover Paloma at Summit Park's Grand Opening Richmond American Homes is thrilled to unveil Paloma at Summit Park, a remarkable community featuring beautifully designed two-story homes starting in the $500s. This exciting new neighborhood is tailored for families and individuals seeking both modern comfort and community vibrancy. Explore Innovative Home Designs At the...

Continue Reading